Skip to content
value.today
Pro Pharmaceuticals Inc. logo

Pro Pharmaceuticals Inc.

Total raised
$2 M
1 round on record
Latest round
$2 M
Dec 2010
First round on record
Dec 2010
Today
Went public
See the company page

Pro Pharmaceuticals Inc. is listed today as Galectin Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Pro Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2016$3 MPrivate placement after listing$2 to $10 million

Pro Pharmaceuticals Inc.: Private sale, Dec 2016

Investors in this round

5 investors had bought by the notice of Jan 6, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pro Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $10 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Harold H. Shlevin · Executive Officer
  • Jack W Callicutt · Executive Officer
  • Peter G Traber · Executive Officer, Director
  • Arthur R Greenberg · Director
  • Gilbert F Amelio · Director
  • Gilbert S Omenn · Director
  • James C Czirr · Director
  • John G. Mauldin · Director
  • Kevin D Freeman · Director
  • Marc G. Rubin · Director
  • Steven G. Prelack · Director
  • Theodore H. Zuconni · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jack Callicutt, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 6, 2017. Read the notice at the SEC.

equity, optionsSEC
Sep 2016$2 MPrivate placement after listingUnder $2 million

Pro Pharmaceuticals Inc.: Private sale, Sep 2016

Investors in this round

1 investor had bought by the notice of Sep 28, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pro Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $12 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Jack W Callicutt · Executive Officer, Director
  • Peter G Traber · Executive Officer, Director
  • Arthur R Greenberg · Director
  • Gilbert F Amelio · Director
  • Gilbert S Omenn · Director
  • James C Czirr · Director
  • John G. Mauldin · Director
  • Kevin D Freeman · Director
  • Marc G. Rubin · Director
  • Steven G. Prelack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter G. Traber, M.D., Chief Executive Officer and President. Source: SEC Form D, newest notice filed Sep 28, 2016. Read the notice at the SEC.

equity, optionsSEC
Dec 2010$2 MNo. 1$2 to $10 million

Pro Pharmaceuticals Inc.: Raise no. 1, Dec 2010

Investors in this round

22 investors had bought by the notice of Jan 12, 2011: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pro Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Anatole C. Klyosov · Executive Officer
  • Anthony D. Squeglia · Executive Officer
  • Eliezer C. Zomer · Executive Officer
  • Maureen D. Foley · Executive Officer
  • Theodore D. Zucconi · Executive Officer, Director
  • Arthur R. Greenberg · Director
  • Gilbert F. Amelio · Director
  • James C. Czirr · Director
  • Jerald F. Rome · Director
  • Peter D. Traber · Director
  • Rod D. Martin · Director
  • S. Colin Neill · Director
  • Steven F. Prelack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Maureen Foley, Chief Operating Officer, Secretary. Source: SEC Form D, newest notice filed Jan 12, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pro Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).

    SEC Form D · Jan 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2017

That is all the official record says: Pro Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Pro Pharmaceuticals Inc. are on record.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Pro Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Gilbert S. OmennPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2015)SEC Form 3
Richard E. UihleinPersonnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 22 investors.

Largest shareholders today

Institutions holding Galectin Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pro Pharmaceuticals Inc.
NameRoleNamed in
Harold H. ShlevinExecutive officerJan 2017
Jack W CallicuttExecutive officerJan 2017
Peter G TraberExecutive officerJan 2017
Anatole C. KlyosovExecutive officerJan 2011
Anthony D. SquegliaExecutive officerJan 2011
Eliezer C. ZomerExecutive officerJan 2011
Maureen D. FoleyExecutive officerJan 2011
Theodore D. ZucconiExecutive officerJan 2011
Arthur R GreenbergDirectorJan 2017
Gilbert F AmelioDirectorJan 2017
Gilbert S OmennDirectorJan 2017
James C CzirrDirectorJan 2017
John G. MauldinDirectorJan 2017
Kevin D FreemanDirectorJan 2017
Marc G. RubinDirectorJan 2017
Peter G TraberDirectorJan 2017
Steven G. PrelackDirectorJan 2017
Theodore H. ZuconniDirectorJan 2017
Jack W CallicuttDirectorSep 2016
Arthur R. GreenbergDirectorJan 2011
Gilbert F. AmelioDirectorJan 2011
James C. CzirrDirectorJan 2011
Jerald F. RomeDirectorJan 2011
Peter D. TraberDirectorJan 2011
Rod D. MartinDirectorJan 2011
S. Colin NeillDirectorJan 2011
Steven F. PrelackDirectorJan 2011
Theodore D. ZucconiDirectorJan 2011

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.